Iran prepares 'aggressive scenarios' against the US https://ymaho.com/iran-prepares-aggressive-scenarios-against-the-us
Brigadier General Shekarchi announced the 'Storm-5' plan and asymmetric strikes. We analyze insider data on Pentagon damage and rising oil prices. Read the analysis.
EMA approval of first-line treatment for aggressive colon cancer https://ymaho.com/ema-approval-of-first-line-treatment-for-aggressive-colon-cancer
EMA recommended encorafenib + cetuximab + FOLFOX for first-line BRAF V600E-mutant mCRC. 47% reduction in risk of progression. Read analysis and BREAKWATER study data.
Leeds Win vs Wolves with Fast Start, Near Safety https://lrivo.com/leeds-win-vs-wolves-with-fast-start-near-safety
Leeds United's aggressive early tactics secured a key Premier League win over Wolves. Analysis of their survival push and FA Cup semi-final focus.
Japanese trend 'Stop Time': enzymes and exosomes instead of anti-age https://ymaho.com/japanese-trend-stop-time-enzymes-and-exosomes-instead-of-anti-age
Japan is abandoning aggressive anti-age in favor of reverse-aging through exosomes and enzymes. Learn about the 'pre-step' skincare trend and cellular correction. Read details.
Enzymatic skin cleansing: enzyme powders instead of peeling https://ymaho.com/enzymatic-skin-cleansing-enzyme-powders-instead-of-peeling
Enzyme powders and masks replace aggressive peels. Gentle pore cleansing without disrupting the skin barrier. Learn about the trend of enzymatic detox without stress for the face.
Slow aging: new Korean trend displaces anti-age in 2026 https://ymaho.com/slow-aging-new-korean-trend-displaces-anti-age-in-2026
Korean slow aging trend displaces aggressive anti-age: PDRN, market growth to $4.3 billion, and why consumers pay more. Read the analysis.
Lung cancer drug Lurbinectedin approved in Europe https://ymaho.com/lung-cancer-drug-lurbinectedin-approved-in-europe
Europe approved the world's first Lurbinectedin drug with immunotherapy for aggressive lung cancer. 46% reduction in risk of death. Learn about the breakthrough and forecasts.
New drug combination for lung cancer therapy: European approval https://ymaho.com/new-drug-combination-for-lung-cancer-therapy-european-approval
European Commission approved Zepzelca and atezolizumab combination for aggressive lung cancer. 27% reduction in risk of death. Learn details about the new standard of therapy.
Probiotics for skin: microbiome cosmetics — trend of the year https://ymaho.com/probiotics-for-skin-microbiome-cosmetics-trend-of-the-year
The probiotic cosmetics market has soared to $1.35 billion. Learn how microbiome care is replacing aggressive cleansing and restoring the skin barrier. It's time to take care of your microflora!
Skin fasting: what it is and who needs simplified skincare https://ymaho.com/skin-fasting-what-it-is-and-who-needs-simplified-skincare
Skin fasting — trend or necessity? Learn how a temporary break from aggressive cosmetics restores the skin barrier and who it suits. Dermatologists' analysis.